Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Clin Lung Cancer
; 7 Suppl 2: S59-63, 2005 Oct.
Article
in En
| MEDLINE
| ID: mdl-16250929
ABSTRACT
Lung cancer is the most common cause of cancer-related death among men and women in the United States. Current trials are focusing on the integration of novel therapeutic agents into current non-small-cell lung cancer (NSCLC) treatment paradigms. Bortezomib, a small-molecule proteasome inhibitor, has single-agent activity in NSCLC and in combination with agents commonly used in NSCLC. This article will review the rationale and preclinical data supporting bortezomib combinations and the clinical trials with bortezomib alone and in combination in NSCLC to date.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Protease Inhibitors
/
Pyrazines
/
Boronic Acids
/
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Clin Lung Cancer
Journal subject:
NEOPLASIAS
Year:
2005
Document type:
Article
Affiliation country:
United States